GRAIL, Inc. reported second quarter 2026 financial results on August 5, 2026. Total revenue grew 26% year-over-year to $44.7 million, driven by a 24% increase in Galleri test revenue to $42.6 million and a 35% rise in test volume to over 61,000. The company reported a net loss of $110.2 million and an adjusted EBITDA loss of $(90.3) million. GRAIL completed a $110 million equity financing with Samsung C&T Corporation and Samsung Electronics Co., Ltd. in June to support commercialization efforts in South Korea. Clinical data from the NHS-Galleri and PATHFINDER 2 studies were presented at the ASCO Annual Meeting, highlighting increased detection of early-stage cancers. The company anticipates an FDA advisory committee meeting in the fall regarding its PMA application for Galleri. GRAIL operates in the healthcare industry, developing multi-cancer early detection tests using next-generation sequencing.